Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa

Cystic Fibrosis Clinical Trial

Official title:

A Multi-Center, Open Label Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin For Inhalation (CFI) Given Daily For 14 Days To Stable Cystic Fibrosis Patients Ages 6 To 17 With Pseudomonas Aeruginosa

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01090908
• Other study ID #: ARD-3100-1001
• Status: Withdrawn
• Start date: September 2010
• Est. completion date: June 2011

Study information

• Verified date: August 2012
• Source: Savara Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in patients with Cystic Fibrosis who have a history of chronic P. aeruginosa lung infection.

Description:

This is a Phase 1/2a, multicenter study, designed to evaluate the pharmacokinetics, safety, and tolerability of once daily administration of 150 mg of Ciprofloxacin for Inhalation (CFI) in patients with Cystic Fibrosis who have a history of chronic P. aeruginosa lung infection. Patients will be enrolled and followed in this study for 1 month. This study will consist of a Screening Phase, a Treatment Phase consisting of a 14 days, and a Follow up Phase consisting of a 14 days Off-treatment Period.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

• 6 to 17 years of age (inclusive) at Visit 1.

• Positive sputum culture for P. aeruginosa

• Clinical diagnosis of CF

• FEV1 greater than or equal to 40% predicted normal lung function

• Able to perform spirometry testing reproducibly according to ATS guidelines.

Exclusion Criteria:

• Use of an investigational agent within 30 days prior to Visit 1 (first dosing visit).

• History of sputum culture or deep-throat cough swab (or BAL) culture yielding Burkholderia cepacia (B. cepacia), within 2 years prior to screening and/or sputum culture yielding B. cepacia at the Screening visit;

• Use of any nebulized or systemic antibiotics within 14 days prior to Visit 1, other than maintenance oral macrolides that has been consistently used for at least 28 days prior to Visit 1.

• History of intolerance or hypersensitivity to quinolone or fluoroquinolone class antibiotics

• History of lung transplantation.

• AST, ALT or total bilirubin > 3 x upper limit of normal at screening.

• History of hemoptysis > 30 cc per episode during the 28 days prior to Visit 1.

• Other present conditions, abnormality in screening laboratory tests or physical examination findings, that in the opinion of the Investigator or Medical Monitor would compromise the safety of the patient or the quality of the data.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• Antibiotic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aradigm Corporation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum pharmacokinetics		Day 1
Secondary	Microbiological efficacy		Day 14
Secondary	Changes in spirometry		Days 1, 7, 14
Secondary	Quality of life (CFQ-R)		Days 1, 7, 14